NS5b GT2
Download full data set here
Sofosbuvir
| | EC50 (uM) | Fold-shift | Phenotype | Replicative Fitness (5) | Clinical RAS | Reference | Comments | | | | | | | | | | | | | | | | | | | | | | | | | |
| WT | 0.037 | 1x | likely susceptible | 100 | | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| H25R | | 0.9x | likely susceptible | 90 | | 8 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| K51R | | 0.9x | likely susceptible | 94 | | 5 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| S62A [Conflicting WT, not used in algorithm] | | | resistance possible | | Yes | 7 | Clincal TE RAS (7) | | | | | | | | | | | | | | | | | | | | | | | | | |
| K100Q | | 1x | likely susceptible | 106 | | 5 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| L159F | | | | | | 4 | EASL 2016 guidelines | | | | | | | | | | | | | | | | | | | | | | | | | |
| T179A | | 1.1x | likely susceptible | | | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| A252V | | | resistance possible | | Yes | 7 | Clincal TE RAS (7) | | | | | | | | | | | | | | | | | | | | | | | | | |
| S282T (GT2a) | 0.175 | 2.8x | resistance likely | 11 | | 2,1,3,4,5, 6 | TE RAV (3, 6) | | | | | | | | | | | | | | | | | | | | | | | | | |
| S282T (GT2b) | | 16.2x | resistance likely | 11 | | 5 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| S282R | | | resistance likely | | | | catalytic triad | | | | | | | | | | | | | | | | | | | | | | | | | |
| S282G | | | resistance likely | | | | catalytic triad | | | | | | | | | | | | | | | | | | | | | | | | | |
| T286P | | 1.3x | likely susceptible | 122 | | 5 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| M289I | | | resistance possible | | Yes | 6 | Clincial TE RAV, 1% (6) | | | | | | | | | | | | | | | | | | | | | | | | | |
| M289L | | 2.0x | likely susceptible | 64 | | 2,5 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| I293L | | 1.3x | likely susceptible | | | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| M434T | | 0.9x | likely susceptible | | | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| H479P | | 1.0x | likely susceptible | | | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| T483M | | 0.9x | likely susceptible | 85 | | 5 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| R498K | | 1.3x | likely susceptible | 126 | | 5 | GT2b | | | | | | | | | | | | | | | | | | | | | | | | | |
| S549N | | 0.8x | likely susceptible | 74 | | 5 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| T179A+M289L | | 2.1x | likely susceptible | | | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| S282T+M289L | | 6.3x | resistance likely | 22 | | 2,5 | replicon selected | | | | | | | | | | | | | | | | | | | | | | | | | |
| S282T+R498K | | 14x | resistance likely | 14 | | 5 | GT2b | | | | | | | | | | | | | | | | | | | | | | | | | |
| M289L+I293L | | 2.5x | resistance possible | | | 2 | replicon selected | | | | | | | | | | | | | | | | | | | | | | | | | |
| T179A+M289L+I293L | | 3.5x | resistance likely | | | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| T179A+S282T+I293L | | 8.3x | resistance likely | | | 2 | replicon selected | | | | | | | | | | | | | | | | | | | | | | | | | |
| T179A+S282T+M289L+I293L | | 9.5x | resistance likely | | | 2 | replicon selected | | | | | | | | | | | | | | | | | | | | | | | | | |
| S282T+M289L+H479P | | 7.4x | resistance likely | | | 2 | replicon selected | | | | | | | | | | | | | | | | | | | | | | | | | |
| S282T+M289L+I293L | | 5.6x | resistance likely | | | 2 | replicon selected | | | | | | | | | | | | | | | | | | | | | | | | | |
| S282T+M289L+I293L+H479P | | 8.4x | resistance likely | | | 2 | replicon selected | | | | | | | | | | | | | | | | | | | | | | | | | |
| S282T+M289L+I293L+M434T | | 7.1x | resistance likely | | | 2 | replicon selected | | | | | | | | | | | | | | | | | | | | | | | | | |
| T179A+S282T+I293L+H479P | | 9x | resistance likely | | | 2 | replicon selected | | | | | | | | | | | | | | | | | | | | | | | | | |
| T179A+S282T+M289L+H479P | | 11.4x | resistance likely | | | 2 | replicon selected | | | | | | | | | | | | | | | | | | | | | | | | | |
| T179A+S282T+M289L+I293L+H479P | | 11.8x | resistance likely | | | 2 | replicon selected | | | | | | | | | | | | | | | | | | | | | | | | | |
| T179A+S282T+M289L+I293L+M434T | | 10.6x | resistance likely | | | 2 | replicon selected | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1. Harvoni US Product Lable |
| 2. Lam et al (2012) AAC 56:3359-3368 |
| 3. Lontok et al. (2015) Hepatology 62.5: 1623-1632. |
| 4. EASL Guidelines 2016 |
| 5. Xu et al. (2017) Antiviral therapy 22:587-97. |
| 6. FDA Vosevi Microbiology Reviews 209195Orig1s000MicroR |
| 7. FDA Microbiology/Virology Reviews Epclusa_ 208341Orig1s000 (2015) |
| 8. Svarovskaia ES, et al. 2014. Clinical Infectious Diseases 59: 1666-74 |
